iRhythm is launching its next generation long-term ambulatory cardiac monitor in the U.S. The new Zio monitor is a prescription-only ECG monitor, which is an integral part of the Zio LTCM service. The ...
SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the commercial launch in Japan of its Zio ® long-term continuous ECG monitoring (LTCM) system, ...
SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) announced the publication of the real-world evidence study: Assessment of Variation in AmbuLatory Cardiac ...
Findings published in the American Heart Journal show higher clinical diagnostic yield and lower odds of retesting with Zio long-term continuous monitoring service (LTCM) compared to other LTCM and ...
iRhythm Technologies IRTC recently announced initial research findings on the post-market, real-world performance of the Zio monitor, IRTC’s next-generation Zio long-term continuous monitoring (LTCM) ...
Findings in a younger, commercially insured population build on Medicare-based CAMELOT results, expanding the generalizability of Zio LTCM's clinical impact across patient groups. Latest data showed ...
SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent ...
SAN FRANCISCO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results